Date: 2012-01-18
Type of information:
Company: Oxford Cancer Biomarkers (UK)
Investors: Quintiles (USA)
Amount: undisclosed
Funding type: private investment
Planned used: The company will develop biomarkers using CancerNav, a proprietary DNA- and protein-based assay technology platform invented by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University.
Others: Quintiles has invested in a new company formed to provide oncology consulting services and new cancer biomarkers,Oxford Cancer Biomarkers.
Quintiles is the largest shareholder in Oxford Cancer Biomarkers; other major shareholders are the University of Oxford, and Professors La Thangue and Kerr.
David Kerr, CBE, DSc, M.D, FMedSci., Professor of Cancer Medicine at the University of Oxford will serve as the new company’s Chief Medical Officer.
Oxford Cancer Biomarkers, with offices in Oxford and Reading, U.K., will have a strategic relationship with Quintiles Consulting and Quintiles Global Laboratories, which have the capabilities and expertise to operationalize the consulting and biomarker R&D innovations from Oxford Cancer Biomarkers for the benefit of biopharma companies globally.
Therapeutic area:
